PTC Therapeutics price target raised to $79 from $78 at Wells Fargo

Wells Fargo raised the firm’s price target on PTC Therapeutics (PTCT) to $79 from $78 and keeps an Overweight rating on the shares. Incremental color from the call points to a positive early launch of Sephience, the firm says. Nearer-term vatiquinone’s potential approval could be another source of upside, though there remains debate on this program, Wells adds.